Loading...
OTCM
MMTZF
Market cap36mUSD
Oct 20, Last price  
0.19USD
Name

Relief Therapeutics Holding SA

Chart & performance

D1W1MN
OTCM:MMTZF chart
P/E
—
P/S
2.58
EPS
—
Vol. 1Y
—
Shs. 5Y
15.78%
Rev. 5Y
60.47%
Div Yld LY
—
Div Yld TTM
—
Revenues
642k
-92.37%
14,827,00014,545,00013,740,000386,382034,932,00020,714,00019,490,000256,11715,0000565,000003,321,0006,081,0006,033,0008,417,000642,000
Net income
-10m
L-42.13%
-2,000,000-9,401,000-12,214,000-19,397,000-59,166,000-1,299,000-12,239,000-12,280,000-9,154,000-16,834,000-2,887,000-436,000-7,460,000-7,828,000-34,705,000-50,790,000-98,181,000-17,119,000-9,906,000
CFO
-7m
L+147.19%
-3,730,900-9,554,639-3,316,076-16,443,609-10,243,841-4,645,876000-2,888,000-1,173,000-618,000-728,000-18,254,000-35,718,000-24,126,000-17,612,000-2,916,000-7,208,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.

Key people

Jeremy Meinen
Chief Financial Officer · since 2024
Giorgio Reiner
Chief Scientific Officer · since 2024
Paolo Galfetti
Chief Business Officer · since 2024
Peter De Svastich
Director · since 2024
Thomas Elzinga
Director · since 2024
Raghuram Selvaraju
Chairman of the Board · since 2016
Gregory Van Beek
Director · since 2024
URL
https://relieftherapeutics.com/
IPO date
Sep 19, 2011
Employees
69
Domiciled in
CH
Incorporated in
CH
Headquarters & legal address
avenue de Sécheron 15
Genève, GE 1202
CH
Previous name
RELIEF THERAPEUTICS Holding SA
Other language
MindMaze Therapeutics Holding AG
Other language
MindMaze Therapeutics Holding Ltd

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT